



## **Exelixis Announces July 30 Webcast of Its Second Quarter 2009 Financial Results Conference Call**

July 16, 2009

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 16, 2009-- Exelixis, Inc. (Nasdaq:EXEL) will release its second quarter 2009 financial results on Thursday, July 30, 2009 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT, in which Exelixis management will discuss the results and provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at [www.exelixis.com](http://www.exelixis.com).

An audio replay of the webcast will be available until 11:59 p.m. EDT/ 8:59 p.m. PDT on August 30, 2009. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888, and the passcode is 72259030.

### **About Exelixis**

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

Source: Exelixis, Inc.

*Exelixis, Inc.*

*Investor Contact:*

*Charles Butler, 650-837-7277*

*Executive Director,*

*Corporate Communications*

[cbutler@exelixis.com](mailto:cbutler@exelixis.com)

*Media Contact:*

*Soleil Maxwell Harrison, 650-837-7012*

*Senior Manager,*

*Corporate Communications*

[sharrison@exelixis.com](mailto:sharrison@exelixis.com)